Anthracimycin

Anthracimycin is a polyketide antibiotic discovered in 2013. Anthracimycin is derived from marine actinobacteria. In preliminary laboratory research, it has shown activity against Bacillus anthracis,[1] the bacteria that causes anthrax, and against methicillin-resistant Staphylococcus aureus (MRSA).[2]

Anthracimycin
Clinical data
ATC code
  • none
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
FormulaC25H32O4
Molar mass396.527 g·mol−1
3D model (JSmol)
  • C[C@@H]1/C=C\C=C\[C@H](OC(=O)[C@@H](C(=O)/C=C(/[C@H]2[C@@H]1C=C[C@@H]3[C@@H]2CC=C(C3)C)\O)C)C
  • InChI=1S/C25H32O4/c1-15-9-11-21-19(13-15)10-12-20-16(2)7-5-6-8-17(3)29-25(28)18(4)22(26)14-23(27)24(20)21/h5-10,12,14,16-21,24,27H,11,13H2,1-4H3/b7-5-,8-6+,23-14-/t16-,17-,18-,19+,20-,21+,24+/m1/s1
  • Key:MHXKMAAKEHGISP-MROKOONJSA-N

Discovery of anthracimycin

Anthracimycin was first isolated from a species of marine Streptomyces (strain CNH365) which was collected off the shore of Santa Barbara, CA.[1] Another strain of Streptomyces (strain T676) isolated off the coast of St. John's Island, Singapore, was found to also produce anthracimycin. This strain was found to contain the biosynthetic gene cluster for anthracimycin production.[3]

Biosynthesis

Anthracimycin is the product of a type I polyketide synthase (PKS). This modular synthetic pathway uses a trans-acyltransferase (AT) domain to load successive units of malonyl-CoA (MCoA) and methylmalonyl-CoA (MMCoA) to build the macrolide backbone. The synthesis is composed of 10 biosynthetic modules consisting of the typical domains associated with PKS biosynthetic pathways (See Figure 1). Formation of the decalin ring is part of the PKS pathway and not a post-tailoring event. This occurs via a spontaneous [4+2] cycloaddition after module 8 (See Figure 2). Cyclization to form the larger lactone ring is the final step of the process by the thioesterase domain.[3]

Figure 1. Architecture of the anthracimycin type I PKS system. Outlined domains are used iteratively. ACP- acyl carrier protein, AD- alcohol dehydrogenase, AT- acyltransferase, D- docking domain, DH- dehydratase, KS- ketoacyl synthase, KR- ketoreductase, MT- methyltransferase, ER- enoylreductase, TE- thioesterase.
Figure 2. Formation of the decalin ring by [4+2] cycloaddition.

Antibiotic activity

Anthracimycin was first noted for its potent activity against Bacillus anthracis (strain UM23C1-1), which is known to cause the human infectious disease anthrax, with a minimum inhibitory concentration (MIC) of 0.031 ug/mL. It was also initially found to have activity against other Gram-positive genera such as staphylococci, enterococci, and streptococci, but was not active against Gram-negative strains.[1] In a follow-up study, anthracimycin was screened against a panel of Staphylococcus aureus strains both in vivo and in vitro. All strains of S. aureus tested were susceptible to anthracimycin at MIC values of less than or equal to 0.25 mg/L. This included strains of methicillin-susceptible, methicillin-resistant (MRSA), and vancomycin-resistant strains. Unfortunately, postantibiotic effects were minimal and the effects of the antibiotic were mitigated by presence of 20% human serum. Nevertheless, levels of anthracimycin significantly below the MIC were still able to slow MRSA growth. The compound was found to be minimally toxic to human cells with an IC50 of 70 mg/L against human carcinoma cells.[4] It has been found that the most likely mechanism of action for anthracimycin is inhibition of RNA and DNA synthesis, but not through DNA intercalation.[4][1] As part of an in vivo study with a murine peritonitis model of infection, anthracimycin was found to protect mice against mortality by MRSA at doses of 1 and 10 mg/kg.[4] As a result, anthracimycin is a promising new scaffold for development of novel antibiotics against MRSA.

References

  1. Jang KH, Nam SJ, Locke JB, Kauffman CA, Beatty DS, Paul LA, Fenical W (July 2013). "Anthracimycin, a potent anthrax antibiotic from a marine-derived actinomycete". Angewandte Chemie. 52 (30): 7822–4. doi:10.1002/anie.201302749. PMC 3821700. PMID 23776159.
  2. "Anthracimycin: New Antibiotic Kills Anthrax, MRSA". Sci-News.com. Sci-News.com. Retrieved 21 July 2013.
  3. Alt S, Wilkinson B (November 2015). "Biosynthesis of the Novel Macrolide Antibiotic Anthracimycin". ACS Chemical Biology. 10 (11): 2468–79. doi:10.1021/acschembio.5b00525. PMID 26349074.
  4. Hensler ME, Jang KH, Thienphrapa W, Vuong L, Tran DN, Soubih E, et al. (August 2014). "Anthracimycin activity against contemporary methicillin-resistant Staphylococcus aureus". The Journal of Antibiotics. 67 (8): 549–53. doi:10.1038/ja.2014.36. PMC 4146678. PMID 24736856.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.